Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04382586 · ClinicalTrials.gov registry record · Phase 2
Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
A Phase 2 study of COVID-19 and COVID-19 Pulmonary Complications, sponsored by BeiGene.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 10
- Study locations
NCT04382586: Completed Phase 2 study of COVID-19 and COVID-19 Pulmonary Complications, sponsored by BeiGene.
NCT04382586 is a Phase 2 study of COVID-19 and COVID-19 Pulmonary Complications that has completed, run by BeiGene. The registered enrollment target is 63 participants, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04382586, a Phase 2 study of COVID-19 and COVID-19 Pulmonary Complications, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 10
- Study locations
Study Summary
The primary objective of this study was to evaluate if the addition of zanubrutinib to supportive care increases the respiratory failure-free survival rate at Day 28 in participants hospitalized for Corona Virus Disease 2019 (COVID-19) and pulmonary distress not receiving mechanical ventilation.
Primary Outcome
Number of participants with respiratory failure-free survival, defined as not having died or gone into respiratory failure on or before Day 28
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Placebo
- DRUG Supportive Care
Study Locations (10)
Massachusetts
- Massachusetts General Hospital - Boston
- The Brigham and Womens Hospital, Inc - Boston
Texas
- Therapeutics Concepts - Houston
- Joe Arrington Cancer Research and Treatment Center - Lubbock
California
- St Jude Medical Center - Fullerton
District of Columbia
- Medstar Heath Research Institute Medstar Washington Hospital Center - Washington D.C.
Georgia
- John D Archbold Memorial Hospital - Thomasville
Illinois
- Loyola University Medical Center - Maywood
New Jersey
- Rutgers University Hospital - Newark
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2020-07-06 |
| Est. Completion | 2021-02-01 |
| Phase | Phase 2 |
What the finished NCT04382586 record still lists
NCT04382586 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 3 interventions - of which Zanubrutinib is the first listed.
NCT04382586 lists 10 locations in 8 states (Massachusetts, Texas, California).
Frequently Asked Questions
What is clinical trial NCT04382586 about?
NCT04382586 is a clinical study titled "Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants". The primary objective of this study was to evaluate if the addition of zanubrutinib to supportive care increases the respiratory failure-free survival rate at Day 28 in participants hospitalized for Corona Virus Disease 2019 (COVID-19) and pulmonary distress not receiving mechanical ventilation.
What is the current status of trial NCT04382586?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2020-07-06. Estimated completion is 2021-02-01.
What conditions does trial NCT04382586 study?
This clinical trial studies the following conditions: COVID-19, COVID-19 Pulmonary Complications.
What interventions are being tested in trial NCT04382586?
The interventions under investigation include: Zanubrutinib (DRUG), Placebo (DRUG), Supportive Care (DRUG).
Who is sponsoring clinical trial NCT04382586?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04382586 being conducted?
This trial has 10 study locations across California, District of Columbia, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04382586's enrollment target sits among peer trials
63 232nd of 298 higher than 67 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI